HAYWARD, Calif., June 14 Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that it has been included on the list of preliminary additions to the Russell 3000Ū Index and the Russell GlobalŪ Index posted by Russell Investments on June 11, 2010 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010. All Russell indexes are subindexes of the Global Index.
"Solta's preliminary addition to the Russell 3000 Index is a positive step for our shareholders and will help increase awareness of our Company," said Stephen J. Fanning, Chairman of the Board, President and CEO. "Inclusion in the Russell 3000 should allow us to expand our range of potential institutional investors as we look to increase our market presence domestically and abroad."
The Russell 3000 Index measures the performance of the 3,000 largest publicly-traded U.S. companies, representing approximately 98% of the U.S. equity market. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. The indexes are reconstituted annually.
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's three premier brands: Thermage(R), Fraxel(R) and Isolaz(R). Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2009, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
SOURCE Solta Medical, Inc.